Annual Financial Report

RNS Number : 5388H

Nuformix PLC

01 August 2019

 

Nuformix Plc

("Nuformix" or the "Company")

2019 Annual Financial Report and Notice of Annual General Meeting

Cambridge, UK, 1 August 2019: Nuformix (LSE: NFX), the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, is pleased to announce that the following documents have been posted to its shareholders:

·     Annual Financial Report 2019

·     2019 Notice of Annual General Meeting

A full pdf version of the Annual Financial Report 2019 together with the Notice of Annual General Meeting will be available for download from the Investor Information section on the Company's website www.nuformix.com.

Copies of the Annual Financial Report 2019 and the Notice of 2019 Annual General Meeting will be submitted to the National Storage Mechanism shortly and be available for inspection at http://www.morningstar.co.uk/uk/NSM.  The Nuformix Annual Financial Report will be filed with the Registrar of Companies in due course and copies can be obtained from the Company Secretary, SGH Company Secretaries Limited, 60 Gracechurch Street, London, EC3V 0HR.

The Annual General Meeting will be held on Tuesday 10 September 2019 at 1.00 pm at the offices of Shakespeare Martineau, 6^th floor, 60 Gracechurch Street, London, EC3V 0HR.

Market Abuse Regulation (MAR) Disclosure. Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the publication of this announcement via a Regulatory Information Service and accordingly, this inside information is now considered to be in the public domain.

Enquiries:

Nuformix plc Dr Dan Gooding, Chief Executive Officer	[phone]
Optimum Strategic Communications Mary Clark, Supriya Mathur Email: [e-mail]	[phone]

About Nuformix plc  www.nuformix.com 

Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix's risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.

Nuformix has created an IP portfolio of granted patents covering cocrystal forms of five small molecule drugs.  Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.

Nuformix was established in Cambridge in 2009 and has invested in pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yielding multiple product opportunities. 

Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L

 

END

 

 

ACSVFLBBKVFFBBB